The stock of Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) last traded at $40.12, up 6.82% from the previous session.
Data from the available sources indicates that Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is covered by 12 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $92.00 and a low of $31.00, we find $75.00. Given the previous closing price of $37.56, this indicates a potential upside of 99.68 percent. ARWR stock price is now 21.86% away from the 50-day moving average and 6.80% away from the 200-day moving average. The market capitalization of the company currently stands at $4.24B.
In total, 2 analysts have assigned it a hold rating, and 9 have given it a buy rating. Brokers who have rated the stock have averaged $69.69 as their price target over the next twelve months.
With the price target of $41, Morgan Stanley recently initiated with Equal-Weight rating for Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). On May 11, 2022, Robert W. Baird Upgraded its previous ‘Neutral’ rating to ‘Outperform’ on the stock reducing its target price from $71 to quote $60, while ‘Goldman’ rates the stock as ‘Buy’.
In other news, San Martin Javier, Chief Medical Officer sold 19,500 shares of the company’s stock on Nov 21. The stock was sold for $584,738 at an average price of $29.99. Upon completion of the transaction, the Chief Medical Officer now directly owns 91,500 shares in the company, valued at $3.67 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 11, Chief Executive Officer Anzalone Christopher Richard sold 146,388 shares of the business’s stock. A total of $7,598,864 was realized by selling the stock at an average price of $51.91. This leaves the insider owning 4,057,634 shares of the company worth $162.79 million. Insiders disposed of 970,060 shares of company stock worth roughly $38.92 million over the past 1 year. A total of 3.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ARWR stock. A new stake in Arrowhead Pharmaceuticals Inc. shares was purchased by ROKOS CAPITAL MANAGEMENT LLP during the first quarter worth $16,085,000. AMALGAMATED FINANCIAL CORP. invested $2,849,000 in shares of ARWR during the first quarter. In the first quarter, GREAT WEST LIFE ASSURANCE CO /CAN/ acquired a new stake in Arrowhead Pharmaceuticals Inc. valued at approximately $2,561,000. AMUNDI acquired a new stake in ARWR for approximately $2,021,000. MOODY ALDRICH PARTNERS LLC purchased a new stake in ARWR valued at around $1,750,000 in the second quarter. In total, there are 401 active investors with 68.10% ownership of the company’s stock.
With an opening price of $38.08 on Thursday morning, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) set off the trading day. During the past 12 months, Arrowhead Pharmaceuticals Inc. has had a low of $26.81 and a high of $70.09. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.90, and a quick ratio of 2.90. The fifty day moving average price for ARWR is $32.92 and a two-hundred day moving average price translates $37.57 for the stock.
The latest earnings results from Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.68, missing analysts’ expectations of -$0.51 by -0.17. This compares to -$0.61 EPS in the same period last year. The net profit margin was -72.40% and return on equity was -42.00% for ARWR. For the current quarter, analysts expect ARWR to generate $67.93M in revenue.
Arrowhead Pharmaceuticals Inc.(ARWR) Company Profile
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.